最新公布的临床研究数据显示,非典型抗精神病药物Caplyta®(活性成分:卢马哌隆)在治疗成人重度抑郁症方面展现出显著疗效,有望成为帮助患者实现临床缓解的新兴治疗选择。该数据进一步验证了其在改善抑郁核心症状方面的潜力,为现有治疗方案提供了重要补充。
最新公布的临床研究数据显示,非典型抗精神病药物Caplyta®(活性成分:卢马哌隆)在治疗成人重度抑郁症方面展现出显著疗效,有望成为帮助患者实现临床缓解的新兴治疗选择。该数据进一步验证了其在改善抑郁核心症状方面的潜力,为现有治疗方案提供了重要补充。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.